Related Experiment Video
Updated: Mar 13, 2026
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.8K
Clinically actionable molecular alterations in Rb-retained small cell lung carcinoma variants.
Martin Zacharias1, Nikolaus John2, Karl Kashofer1
1Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Virchows Archiv : an International Journal of Pathology
|March 11, 2026
Summary
Rb-retained small cell lung cancer (SCLC) shows distinct molecular features. Two cases revealed actionable oncogenic drivers, suggesting targeted therapies may benefit this SCLC subgroup.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small cell lung cancer (SCLC) is typically characterized by RB1 and TP53 gene inactivation.
- A subset of SCLC tumors retains Retinoblastoma protein (Rb) expression, presenting unique molecular profiles.
Purpose of the Study:
- To characterize the molecular landscape of Rb-retained SCLC.
- To identify potential therapeutic targets in this distinct SCLC subgroup.
Main Methods:
- Case study analysis of two patients with Rb-retained SCLC.
- Comprehensive molecular profiling, including genomic alterations and gene fusions.
- Clinical assessment of treatment response.
Main Results:
- Case 1: KRAS p.G12C mutation and CCND1 amplification, responding to sotorasib.
- Case 2: TP53 mutation, CDKN2A loss, STK11 inactivation, and an IKZF2::ERBB4 fusion.
- Both cases exhibited complex copy number alterations and small cell morphology with variant features.
Conclusions:
- Rb-retained SCLC exhibits significant molecular heterogeneity.
- Clinically actionable oncogenic drivers are present in Rb-retained SCLC.
- Routine Rb expression assessment and molecular profiling are crucial for identifying therapeutic targets in SCLC.
